Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

The relatively recent development of hormone receptors and human epidermal growth factor receptor 2 (HER2) as validated targets ... because of low pCR rates, although this evidence is generally ...

Risk of relapse score (high vs. low): risk of recurrence in patients with newly diagnosed HER2+ breast cancer. pCR likelihood score (high vs. medium vs. low): likelihood of a patient responding to ...

Then for those patients who didn't get to pCR, we can give more intensive treatment ... has compiled an impressive record as treatment for HER2-positive breast cancer. The agent outperformed ...